Haleon has posted a 10.5% jump in adjusted operating profit to £2.5bn in its latest annual results.

The consumer healthcare group also reported organic revenue growth of 3% for the year, although it stated this was below expectations, citing a “weak cold and flu season”, as well as low consumer confidence in North America

Haleon, whose brands include Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins, was publishing its annual results covering the 12 months in 2025. It estimated that the headwind from the weaker cold and flu season was a 150 basis points (BPS) impact in Q4 on organic revenue growth, and 40 bps for the full year.

The FTSE 100 company emerging markets, which accounted for approximately 36% of revenues, delivered organic revenue growth of 6.4%, including double digit growth in India and mid-single digit growth in China.

“Our brands again proved their resilience, and we continued to outperform the market, with 60% of the business gaining or maintaining share this year,” Haleon CEO, Brian McNamara, commented.

“Organic revenue growth of 3% was below our medium-term expectations, primarily reflecting a weak cold & flu season and low consumer confidence in North America. We delivered strong gross margin improvement and double-digit organic profit growth, combined with strong cash generation.

“This was driven by excellent progress against our productivity programme and continued disciplined investment behind our brands, innovation and capabilities.”

In an outlook for the 2026 financial year, Haleon is expecting further organic revenue growth of 3-5%, with a “high-single digit” adjusted operating profit growth at constant currency.

“Looking ahead, we remain confident in our medium-term guidance underpinned by the implementation of our new operating model to drive growth and agility,” McNamara added. “While the consumer environment remains challenging near-term, we are even more focused on driving category growth and increasing our market outperformance.”

---